EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSCHOG00000005953
Gene Symbol: CACNA2D1
1 Cross references
288 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSCHOG00000005286
Gene Symbol: CACNA2D3
1 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSCHOG00000007069
Gene Symbol: CACNB3
1 Cross references
278 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSCHOG00000003080
Gene Symbol: CACNB4
1 Cross references
251 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 3

Ensembl ID : ENSCHOG00000012653
Gene Symbol: CACNG3
1 Cross references
258 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSCHOG00000007661
Gene Symbol: CACNA1D
1 Cross references
280 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSCHOG00000001754
Gene Symbol: CACNA1E
1 Cross references
295 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSCHOG00000012312
Gene Symbol: CNR2
1 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSCHOG00000013483
Gene Symbol: CA12
1 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSCHOG00000002570
Gene Symbol: CA13
1 Cross references
291 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSCHOG00000011355
Gene Symbol: CA14
1 Cross references
211 Possible Orthologues:

Carbonic Anhydrase 2

Ensembl ID : ENSCHOG00000000722
Gene Symbol: CA2
1 Cross references
285 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).